BioMed Research International

BioMed Research International / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 470393 |

Rui Liu, Jin-ze Li, Jun-ke Song, Jia-lin Sun, Yong-jie Li, Si-bai Zhou, Tian-tai Zhang, Guan-hua Du, "Pinocembrin Protects Human Brain Microvascular Endothelial Cells against Fibrillar Amyloid- β1−40 Injury by Suppressing the MAPK/NF- κ B Inflammatory Pathways", BioMed Research International, vol. 2014, Article ID 470393, 14 pages, 2014.

Pinocembrin Protects Human Brain Microvascular Endothelial Cells against Fibrillar Amyloid- β1−40 Injury by Suppressing the MAPK/NF- κ B Inflammatory Pathways

Academic Editor: Nikunj Patel
Received07 Apr 2014
Revised02 Jun 2014
Accepted15 Jun 2014
Published23 Jul 2014


Cerebrovascular accumulation of amyloid-β (Aβ) peptides in Alzheimer’s disease (AD) may contribute to disease progression through Aβ-induced microvascular endothelial pathogenesis. Pinocembrin has been shown to have therapeutic effects in AD models. These effects correlate with preservation of microvascular function, but the effect on endothelial cells under Aβ-damaged conditions is unclear. The present study focuses on the in vitro protective effect of pinocembrin on fibrillar Aβ1−40 (fAβ1−40) injured human brain microvascular endothelial cells (hBMECs) and explores potential mechanisms. The results demonstrate that fAβ1−40-induced cytotoxicity in hBMECs can be rescued by pinocembrin treatment. Pinocembrin increases cell viability, reduces the release of LDH, and relieves nuclear condensation. The mechanisms of this reversal from Aβ may be associated with the inhibition of inflammatory response, involving inhibition of MAPK activation, downregulation of phosphor-IKK level, relief of IκBα degradation, blockage of NF-κB p65 nuclear translocation, and reduction of the release of proinflammatory cytokines. Pinocembrin does not show obvious effects on regulating the redox imbalance after exposure to fAβ1−40. Together, the suppression of MAPK and the NF-κB signaling pathways play a significant role in the anti-inflammation of pinocembrin in hBMECs subjected to fAβ1−40. This may serve as a therapeutic agent for BMEC protection in Alzheimer’s-related deficits.

1. Introduction

Brain microvascular endothelial cells (BMECs) contribute to the formation of the blood-brain barrier (BBB) and are indispensable to the creation and maintenance of brain homeostasis. They are also the early targets of various toxic molecules, such as amyloid-β peptides (Aβ) and reactive oxygen species (ROS), of neurodegeneration [1, 2]. Recent findings demonstrate that fibrillar Aβ (fAβ) accumulates not only in the brain parenchyma but also at sites in the cerebrovasculature, particularly around arterioles and capillaries of the cerebral cortex and leptomeninges, resulting in cerebral amyloid angiopathy (CAA) [3, 4]. CAA is closely correlated with Alzheimer’s disease (AD) and affects 80–90% of AD patients [46]. The pathology of microvascular CAA is associated with cerebrovascular dysfunction, including destruction of the blood-brain barrier (BBB) and enhancement in vessel-associated inflammation [4, 68].

In AD, cerebrovascular amyloid deposition primarily comprises aggregated Aβ. Cerebrovascular deficiencies involved in CAA are paralleled by Aβ-mediated responses in cultured endothelial cells [911], indicating that Aβ can elicit cerebrovascular deficits that contribute to disease progression. In particular, Aβ treatment of endothelial monolayers augments monocyte adhesion and subsequent transendothelial migration [1214], reduces endothelial antioxidant efficacy [1517], stimulates inflammatory responses [18], and increases endothelial permeability [11, 19, 20]. In this way, endothelial damage appears to be associated with the activation of multiple types of signal transduction. Aβ stimulates the production of ROS, which may be important signaling molecules in endothelial pathological events, especially inflammation [21]. ROS may act as second messengers through the activation of many intracellular signaling pathways, such as mitogen-activated protein kinases (MAPKs) and transcription factors, notably nuclear factor-kappa B (NF-κB). The MAPKs are a group of serine and threonine kinases. They regulate gene expression by modulating transcription factors such as NF-κB [22]. They have also been implicated in inflammatory and cell death pathways on cerebral damage [23, 24]. The NF-κB signal pathway, which is activated by ROS-dependent mechanisms [25, 26], also plays an important role in the gene expression of a large number of proinflammatory cytokines. In this way, the hope of counteracting these deleterious events might involve strategies aimed at interrupting the oxidant and inflammatory cascades.

Pinocembrin (5,7-dihydroxyflavanone, Figure 1) is a flavonoid abundant in propolis. It can be extracted as a pure compound and has been shown to be effective in the protection of brain injury from ischemic and Aβ impairment. In 2008, it was approved by the State Food and Drug Administration of China for the treatment of stroke. Pinocembrin was shown to protect against ischemic injury and reduce the area of cerebral infarction in ischemia models via neurovascular protection by decreasing the severity of oxidative damage and inhibiting inflammatory responses [2729]. It was also demonstrated that pinocembrin protected the BBB from ischemic injury by mitigating ultrastructural damage, reducing permeability, improving microvascular blood flow, and protecting BMECs from oxygen-glucose deprivation/reoxygenation-induced toxicity [30]. Recently, pinocembrin was found to alleviate cognitive deficits in intracerebroventricular Aβ-injected and Aβ-precursor protein (APP)/presenilin 1 (PS1) double transgenic AD mouse models [31, 32]. It has also been shown to attenuate cerebral degeneration in AD by inhibiting inflammatory pathways mediated by the receptor for advanced glycation end products and to be involved in the preservation of the microvascular function, maintenance of the BBB integrity, and reduction of inflammatory mediator levels [31, 32]. Relative studies have demonstrated beneficial effects of pinocembrin in endothelial cells, such as the improvement of the biological functions of endothelial progenitor cells and the suppression of vascular endothelial growth factor-induced angiogenesis in the mouse aortic ring [33, 34]. Although previous studies have suggested that pinocembrin may show protection in endothelial cells from insults, no preexisting study has reported the direct effect of pinocembrin on brain microvascular endothelial cells mediated by Aβ.

Therefore, current in vitro studies are yet to be conducted to investigate the effect of pinocembrin on human BMECs (hBMECs) in the fAβ1–40 damaged condition and explore its mechanism during inflammatory processes.

2. Material and Methods

2.1. Cell Culture and Treatment

hBMECs were purchased from ScienCell Research Laboratories (ScienCell Research Laboratories, Carlsbad, CA, USA). The hBMECs were cultured in endothelial cell complete medium (ScienCell Research Laboratories, Carlsbad, CA, USA) in a 37°C incubator with 5% CO2, according to the supplier’s recommendations. Experiments were conducted within cell passages 4–6. At these passages, cells displayed a cobblestone appearance, which is morphologically normal for endothelial cells. All treatments were performed after the hBMECs were 60–70% confluent.

Synthetic fAβ1–40 was purchased from Sangon Biotech Company (Shanghai, China) and dissolved in water to make a stock solution of 0.1 mM to foster the fibrillization state, as previously reported [35, 36]. Pinocembrin (purity > 99%) was synthesized by the Institute of Materia Medica of the Chinese Academy of Medical Sciences. It was first dissolved in DMSO at 100 mM and then diluted in endothelial cell medium at 30.0 μM, 10.0 μM, and 3.0 μM. Different concentrations of pinocembrin were added at the start of fibrillar fAβ1–40 injury, and then both were incubated for 24 h. hBMECs were randomly divided into groups: (1) control group, (2) control group treated with 3 μM, (3) control group treated with 10.0 μM, (4) control group treated with 30 μM pinocembrin for 24 h, (5) fAβ1–40 group treated with 20 μM fAβ1–40 for 24 h, (6) fAβ1–40 group treated with 3 μM, (7) 10 μM, and (8) fAβ1–40 group treated with 30.0 μM pinocembrin for 24 h.

2.2. MTS Assay for Cell Viability

Cell survival was evaluated using MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay (Promega, Madison, WI, USA) according to the manufacturer’s protocol and detected in a SpectraMax Plus microplate reader (Molecular Devices Corp., Sunnyvale, CA, USA).

2.3. Lactate Dehydrogenase (LDH) Release Assay

LDH released from hBMEC-compromised membranes was determined using a CytoTox-ONE Homogeneous Membrane Integrity Assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Briefly, cells were grown to 70% confluence in 96-well culture plates and were exposed to fAβ1–40, pinocembrin, or both for the indicated lengths of time. Then 50 μL culture supernatants were transferred to a separate assay plate, leaving behind the cells that were used for Hoechst 33343 and ROS detections. Then 50 μL of CytoTox-ONE Reagent was added to each well, and the contents of the plates were mixed for 30 s. The LDH assay was allowed to proceed at room temperature for 10 min prior to an addition of 25 μL/well stop solution containing 10% sodium dodecyl sulfate. The contents of the wells were mixed by shaking the plates for 10 s prior to measurement of resorufin fluorescence (560 nm excitation/590 nm emission).

2.4. Hoechst 33342 and DCFH2-DA Staining Assay

Nuclear change and intracellular ROS level were measured in hBMECs using Hoechst 33342 (Dojindo Laboratory, Kumamoto, Japan) and DCFH2-DA (2′,7′-dihydrodichlorofluorescein diacetate, Sigma Chemical Co., St. Louis, MO, USA) staining, respectively. Nuclei were labeled with 5 μg/mL of Hoechst 33342 at 37°C for 10 min after the fAβ1–40 injury or pinocembrin treatment. ROS was measured based on the oxidation of DCFH2-DA to 2′,7′-dichlorofluorescein, and DCFH2-DA was added to the culture plates at a final concentration of 5 μM at 37°C for 40 min. The intensity of fluorescence was detected and analyzed by a Cellomics ArrayScan HCS Reader (Cellomics Inc., Pittsburgh, PA, USA) provided with the Morphology Explorer BioApplication software. The images were acquired using the 386/23 nm excitation/460/40 nm emission and 485/20 nm excitation/535/50 nm emission filters, respectively. Nuclear change and ROS level were quantified by the value of average fluorescent intensity [31].

2.5. Intracellular Superoxide Dehydrogenase (SOD) and Glutathione Peroxidase (GSH-Px) Assay

After the fAβ1–40 injury and pinocembrin treatment, hBMECs were collected and crushed by sonication (60 W at 0.5 s intervals for 10 min). The cell lysate was centrifuged at 10,000 g for 15 min, and the supernatant was used to measure the activities of SOD and GSH-Px using a WST-1 based SOD inhibition kit (Dojindo Laboratory, Kumamoto, Japan) and a GSH-Px detection kit (Jiancheng Bioengineering, Nanjing, China), respectively. The solutions in each well were added according to the manufacturer’s protocols. The absorbance of the endpoint reactions was measured using a SpectraMax Plus microplate reader (Molecular Devices Corp., Sunnyvale, CA, USA). The relative SOD inhibition of each sample was calculated using the following equation: , where , , , and were the absorbance at 440 nm for the uninhibited test, blank sample, blank reagent, and sample, respectively [37]. GSH-Px activity was determined by quantifying the rate of oxidation of reduced GSH to oxidized GSH by H2O2 and catalyzed by GSH-Px. One unit of GSH-Px was defined as the amount that could reduce the level of GSH at 412 nm by 1 μM in 1 min per mg of protein.

2.6. MAPK Signal Pathways and NF-κB p65 Translocation Assays

The MAPK signal pathways and NF-κB p65 translocation were detected by immunofluorescence assay and quantified on the Cellomics ArrayScan high-content analysis platform. hBMECs were subcultured in black-walled optically clear-bottomed 96-well plates (Corning Life Sciences, Acton, MA, USA). After treatment with fAβ1–40 and pinocembrin as described above, cells were fixed with 4% paraformaldehyde, permeabilized with 0.3% Triton X-100, and then blocked with 3% BSA. The primary antibody mixture containing antiphosphor-ERK1/2 (Thr202/Tyr204) mouse monoclonal (1 : 250, Cell Signaling, Beverly, MA, USA), antiphosphor-p38 (Thr180/Tyr182) rabbit polyclonal (1 : 400, Cell Signaling), anti-phosphor-MAPKAP kinase-2 (MK2) (Thr334) rabbit polyclonal (1 : 200, Cell Signaling), anti-phosphor-SAPK/JNK (Thr183/Tyr185) mouse monoclonal (1 : 400, Cell Signaling), anti-phosphor-c-Jun (Ser73) mouse monoclonal (1 : 200, Cell Signaling), or anti-NF-κB p65 rabbit polyclonal (1 : 250, Invitrogen, Carlsbad, CA, USA) antibodies in PBS was incubated at 4°C overnight. After washing with PBS, the cells were incubated with corresponding AlexaFluor 488 or 546-conjugated goat anti-rabbit/mouse secondary antibodies (1 : 500, Invitrogen, Carlsbad, CA, USA) at room temperature for 1 h. The fluorescence images were acquired using the Cellomics ArrayScan HCS Reader provided with the Cytoplasm to Nucleus Translocation BioApplication [31, 38].

Briefly, images were acquired in independent channels with fixed exposure times. Based on the Hoechst nuclear staining, a nuclear region mask was created and used to quantify nuclear protein distribution. By expanding the nuclear region mask, a concentric ring was generated and used as an approximation of the cytosolic compartment. Cytosolic and nuclear staining intensities were normalized to total nuclear region and cytosolic ring area, allowing for the quantification of protein translocation between the nucleus and cytosol for phosphor-ERK1/2, phosphor-p38, phosphor-MK2, phosphor-SAPK/JNK, and NF-κB p65. The capacity of translocation of the four proteins was illustrated by the value of Mean_CircRingAvgIntenDiff. For the c-Jun detection, nuclear fluorescence intensity was acquired and calculated as the value of protein expression.

2.7. Western Blot Analysis

The hBMECs were grown in 10 cm cell culture dishes, exposed to fAβ1–40 plus pinocembrin at the indicated concentrations, and washed twice with PBS before harvesting proteins using ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 20 mM EDTA, 0.1% sodium dodecyl sulfate, 100 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM PMSF, 2 mM sodium pyrophosphate, 1 μg/mL pepstatin A, 100 μg/mL leupeptin, and 1 × protease inhibitor cocktail, Roche Molecular Biochemicals, Indianapolis, IN, USA). The lysates were centrifuged and the resulting supernatant was collected for detection. The samples were separated by SDS-PAGE electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked in Tris-buffered saline and Tween-20 (TBST, pH 7.6) containing 5% nonfat dry milk powder at room temperature for 2 h. The blocks were probed with anti-IκB (inhibitor of kappaB) α antibody (1 : 500), anti-phosphor-IKK (I kappaB kinase) α antibody (1 : 1000), anti-IKKα antibody (1 : 1000), anti-phosphor-IKKβ antibody (1 : 1000), and anti-IKKβ antibody (1 : 1000) (Cell signaling, Beverly, MA, USA), respectively, and then with horseradish peroxidase-labeled secondary antibodies (1 : 2000, ZSGB-Bio, Beijing, China). Each membrane was stripped and reprobed with mouse anti-actin antibody which served as a loading control. Relative optical densities and areas of bands were quantified using an imaging densitometer.

2.8. ELISA Assay for Tumor Necrosis Factor α (TNF-α), Interleukin-1β (IL-1β), and Interleukin-6 (IL-6)

Group divisions and treatments were as described above. The culture medium was collected and centrifuged for 10 min at 4°C to eliminate the cell debris. The proinflammatory cytokines of TNF-α, IL-1β, and IL-6 in culture medium were measured by ELISA assays. Quantitative levels were measured according to the manufacturer’s instructions (Jiameinuosi Biotech, Beijing, China). The optical density was measured at 450 nm, and values were calculated with reference to standard curves.

2.9. Statistical Analysis

All data are represented as the mean ± the standard error of the mean (SEM). Comparisons were performed using one-way analysis of variance (ANOVA), and multiple comparisons were performed using post-hoc least significant difference comparisons. A value of <0.05 was considered statistically significant.

3. Results

3.1. Pinocembrin Protects hBMECs from fAβ1–40-Induced Cytotoxicity

In the present study, the direct protective effects of pinocembrin on hBMECs against fAβ1–40-induced toxicity were examined in three cytotoxicity assays. In the MTS assay, cell viability was found to be significantly decreased in the presence of 20 μM fAβ1–40 in hBMECs (Figure 2(a),  ). Pinocembrin increased cell viability at 3.0 μM, 10.0 μM, and 30.0 μM after exposure to 20 μM fAβ1–40 in a dose-dependent manner (,  ,   ). Pinocembrin did not show significant effects on hBMECs without fAβ1–40 treatment at any of the concentrations evaluated here.

A similar effect was seen in the LDH release assay. Concentrations of 20 μM fAβ1–40 produced significant enzyme leakage from hBMECs (Figure 2(b),  ), and the intensity of fluorescence based on the release of LDH in cells treated with pinocembrin decreased significantly at 3.0 μM, 10.0 μM, and 30.0 μM in a dose-dependent manner (,  ). Pinocembrin did not affect the release of LDH from hBMECs without fAβ1–40 treatment at the same concentrations.

The cytoprotective effects of pinocembrin were confirmed in nuclear changes by Hoechst 33342 staining as well. Control hBMECs were uniformly stained with faint blue fluorescence. In contrast, hBMECs treated with fAβ1–40 showed denser nuclei with more intense fluorescence indicating nuclear shrinkage or condensation which is one of the early signs of damage (,   Figures 2(c) and 2(d)). These cytotoxic effects were alleviated in both nuclear morphological condensation and fluorescence through the treatment with pinocembrin at 3.0 μM, 10.0 μM, and 30.0 μM (,  ). Pinocembrin detected at the same concentrations did not damage the nuclei of control cells.

Based on the above results, pinocembrin at the determined concentrations of 3.0 μM, 10.0 μM, and 30.0 μM is found to significantly increase the viability of cells, decrease the level of LDH, and relieve the injury of nucleus injured by fAβ1–40. Pinocembrin detected at the same concentrations did not show effects in these cytotoxicity assays. Due to the dose-dependent manner in which pinocembrin is found to act, concentrations ranging from 3.0 μM to 30.0 μM are selected for further investigation in hBMECs in the presence to fAβ1–40.

3.2. Pinocembrin Cannot Remarkably Regulate the Redox Imbalance of hBMECs against fAβ1–40-Induced Toxicity

Aβ exerts toxicity against the endothelial cells of the brain via enhanced ROS production and redox imbalance [37, 39]. In this study, fAβ1–40 increased endogenous ROS generation in hBMECs by about 2.95-fold (, Figures 3(a) and 3(b)). fAβ1–40 also reduced endothelial antioxidant efficacy through decreasing GSH-Px and SOD activities, two markers of oxidative stress, to 43.36% and 58.82%, respectively (, Figures 3(c) and 3(d)). These effects indicated a severe redox imbalance in this endothelial cell model. However, pinocembrin neither decreased the ROS generation nor increased GSH-Px or SOD activity in the present model at the concentrations evaluated here, suggesting that pinocembrin cannot exert sufficient effects on amelioration of the antioxidative ability of hBMECs subjected to fAβ1–40-induced toxicity.

3.3. Pinocembrin Inhibits the MAPK Pathways in hBMECs against fAβ1–40-Induced Toxicity

MAPKs are regulated by ROS in endothelial cells to express the proinflammatory phenotype through the phosphorylation activation and the subsequent nuclear transduction [4042]. Here, in control hBMECs, basal levels of phosphor-p38 and phosphor-MK2 were significantly confined to the cytosolic and nuclear compartment, showing a low and a high Mean_CircRingAvgIntenDiff value, respectively. Depending on stimulus of fAβ1–40, phosphor-p38 and phosphor-MK2 translocation were activated, as illustrated by the significant increase and a marked decrease in Mean_CircRingAvgIntenDiff values, respectively (, Figures 4(a) and 4(b)). Pinocembrin treatment significantly inhibited the p38 MAPK pathway. The translocation of cytosolic phosphor-p38 to the nucleus and nuclear phosphor-MK2 to the cytoplasm was significantly inhibited at concentrations of 3.0 μM, 10.0 μM, and 30.0 μM in a dose-dependent manner (, , ).

The basal level of phosphor-SAPK/JNK was confined to the cytosolic compartment, shown as a low Mean_CircRingAvgIntenDiff value in control hBMECs. Similarly, its downstream phosphor-c-Jun was seen in low average fluorescence intensity in the nucleus. After fAβ1–40 treatment, phosphor-SAPK/JNK translocation was promoted by a significant increase in Mean_CircRingAvgIntenDiff values (, Figures 4(a) and 4(c)). The level of phosphor-c-Jun increased by 3.6-fold, as indicated by average intensity of fluorescence in the nucleus (, Figures 4(a) and 4(d)). Pinocembrin treatment was found to significantly inhibit the SAPK/JNK pathway. The translocation of cytosolic phosphor-SAPK/JNK to the nucleus and the upregulation of phosphor-c-Jun were inhibited at concentrations of 3.0 μM, 10.0 μM, and 30.0 μM in a dose-dependent manner (, , Figures 4(a), 4(c), and 4(d)). Similarly, phosphor-ERK1/2 translocation was activated by showing a significant increase in the Mean_CircRingAvgIntenDiff value in fAβ1–40-treated hBMECs (, Figures 4(a) and 4(e)), and pinocembrin was shown to significantly inhibit translocation of cytosolic phosphor-ERK1/2 to the nucleus at 30.0 μM ().

3.4. Pinocembrin Regulates NF-κB Signal Pathway and Inhibits the Release of Proinflammatory Cytokines in hBMECs against fAβ1–40-Induced Toxicity

Activation of NF-κB is a central event in the inflammatory response, and optimal activation of NF-κB requires the release of p65 from IκB following the phosphorylation of the IκB proteins by a complex of IκB kinases. fAβ1–40 was found to induce upregulation in phosphorylation levels of IKKα and IKKβ (, Figures 5(a) and 5(b)), decrease the levels of IκBα (, Figures 5(a) and 5(c)), and increase the NF-κB p65 distribution in nucleus (, Figures 5(d) and 5(e)). The levels of TNF-α, IL-1β, and IL-6 in culture medium were increased as well (, Figures 5(f)5(h)). Compared with the fAβ1–40-treated hBMECs, quantitative analysis revealed statistically significant downregulation of phosphorylation levels of IKKα and IKKβ in 30 μM pinocembrin-treated group (). Besides for this effect, pinocembrin markedly suppressed the activation of NF-κB signal transduction through blockage of the degradation of IκBα and inhibition of the nuclear translocation of NF-κB p65 at concentrations of 3.0 μM, 10.0 μM, and 30.0 μM in a dose-dependent manner (, , , Figures 5(a) and 5(c)5(e)). The levels of TNF-α, IL-1β, and IL-6 in culture medium were also significantly decreased by pinocembrin in the fAβ1–40-treated hBMEC model (, , , Figures 5(f)5(h)).

4. Discussion

As an extension of previous research, the present study clarified the beneficial effects of pinocembrin on AD-associated microvascular endothelial pathology. The present findings indicate that pinocembrin can protect hBMECs from fAβ1–40-induced toxicity. In these effects, pinocembrin increases cell viability, reduces the amount of LDH release, relieves nuclear condensation, inhibits the MAPK pathways, relieves IκBα degradation, blocks NF-κB p65 nuclear translocation, and reduces the levels of extracellular proinflammatory cytokines. In addition, pinocembrin can inhibit phosphor-IKK activation modestly. However, pinocembrin does not show remarkable effects on the regulation of redox imbalances. Pinocembrin’s ability to protect microvascular endothelial cells from fAβ1–40 mainly contributes to anti-inflammation.

The microvascular endothelial cells of the brain form a highly specialized endothelial tissue that serves as the BBB. These cells appear to be a primary target and an important responsive component of cerebral inflammation in AD [1, 2]. Cerebrovascular Aβ deposition plays a role in the progression of AD. Fibrillar Aβ accumulates at sites in the cerebrovasculature, particularly around arterioles and capillaries of the cerebral cortex and leptomeninges [3, 4]. This phenomenon is present in more than 80% of AD patients, and cerebrovascular amyloidosis is causally involved in the development of neurodegeneration in this disease [42].

Given experimental data reporting the contradictory findings of Aβ toxicity in endothelial cell culture [9, 10, 43], the present work first involved confirmation of whether fAβ1–40 treatment causes any significant cell death in the present experimental paradigm. In line with the decreased viability of hBMECs in the presence of fAβ1–40, the increased release of LDH and the injury of nuclei were observed in the same manner. These results demonstrate that fibrillar fAβ1–40 is directly toxic to hBMECs.

Herein, the effective administration conditions for pinocembrin were screened using both control and fAβ1–40-injured hBMECs in the first step. Pinocembrin at the determined optimal concentrations of 3.0 μM, 10.0 μM, and 30.0 μM is found to significantly increase the viability of cells injured by fAβ1–40. Results of the decrease of LDH release and the relief of nuclear injury also indicate the protective effects of pinocembrin on this process. It is here confirmed that there are no differences among the pinocembrin treatments in control cells, indicating that pinocembrin has no toxic effect under basal conditions.

Oxidative stress is implicated in AD pathology. Excessive generation of ROS within endothelial cells in response to Aβ leads to oxidative stress and cellular injury [39]. In vitro studies have revealed that oxidative stress results in dysfunction of the endothelial cell, destroying the integrity of the vascular barrier and leading to increased endothelial permeability, mitochondrial dysfunction, generation of cytokines, chronic inflammatory processes, and amyloid deposition in blood vessels, which are involved with the imbalance of endothelial transductions during the pathogenesis of Alzheimer’s deficits [11, 19, 4448]. A strategy involving neuroprotective properties is here recommended for reduction of the severity of oxidative injury and maintaining the integrity of the BBB for the treatment of brain damage.

Pinocembrin is a flavonoid so that it might be thought to be effective in quenching free radicals. Here, pinocembrin merely produced a slight increase in the effectiveness of the antioxidant defense system of hBMECs when subjected to fAβ1–40. Pinocembrin was reported to possess a limited antioxidative effect in ischemia models [28, 29], but it is not found to produce sufficient effects on the regulation of the redox imbalance under the conditions that are rich in Aβ [31, 32]. In general, the cytoprotective capacity of flavonoids against different insults has been mainly attributed to their antioxidant potency [49, 50]. Nonetheless, cytoprotection of flavonoids was no more defined to be correlated with the antioxidation potency [51]. The report that the hydroxy substitutions in the A-ring (C5 and C7) and in position C3 (C-ring) of the flavones would be necessary to afford neuroprotection indicated that the structural requirements for cytoprotection are different from those that afford antioxidant capacity [52]. Additionally, many flavonoids show an important pharmacological effect on modulating the activities of protein kinases, lipid kinases, and enzymes of mitochondrial respiratory chain independent of their antioxidant capacity [5355]. Therefore, although antioxidation is not involved in the major mechanisms that prevent Aβ-mediated toxicity, pinocembrin may act synergistically with other crucial mechanisms for the treatment in our experimental model.

The MAP kinase family is correlated with activation of intracellular signal events during the pathological process of AD. To date, at least three major MAPK cascades have been described that involve the activation of ERK, SAPK/JNK, and p38 MAPK in the brain. The ERK cascade is mostly responsive to mitogenic and differentiation stimuli, whereas the JNK and p38 MAPK pathways are preferentially activated by proinflammatory cytokines and extracellular stress [56] and contribute to the regulation of synaptic function, the BBB permeability, inflammatory response, and apoptotic process [5759]. One type of stress that induces potential activation of MAPK pathways is the oxidative stress caused by ROS. In case MAPK-signaling pathways are activated, several inflammatory cytokines are further overproduced and released [56].

MAPK activation may be secondary to many different extracellular stimuli, but the series of phosphorylation cascade activation events are critical to the responses. Our results showed that fAβ1–40 exposure induced activation of ERK1/2, p38 MAPK/MK2, and SAPK/JNK-c-Jun cascades secondary to overproduction of ROS in the hBMECs. This is consistent with the results of the proinflammatory nature of the MAPK pathway [60]. Pinocembrin is found to markedly inhibit the activation of phosphorylated p38 MAPK/MK2 and SAPK/JNK-c-Jun pathways at each tested concentration, and only the high concentration (30 μM) was effective in the blockade of phosphor-ERK1/2 activation. These results are essentially consistent with the finding that pinocembrin modulates transduction of these MAPKs in neuronal and endothelial cells as in previous reports as well [31, 32]. Besides, many molecular components are involved in apoptosis tightly linked to the presence and activation of MAPK family, one of which is the JNK-mediated cytochrome release contributing to caspase-3 activation and the onset of apoptosis [61, 62]. Therefore, these inseparable processes can be inhibited not only by antioxidant treatment but also by MAPK activation inhibition [6365]. Although pinocembrin does not show strong antioxidative effects through the clearance of ROS, coincided with the reversal from the endothelial injury, it is plausible that pinocembrin treatment attenuates fAβ1–40-induced cytotoxicity, at least in part, through the inhibition of ERK1/2, SAPK/JNK, and p38 cascades. However, in this study, we only determined the effect of pinocembrin on translocation cascades of MAPKs following the phosphorylation. It is worth investigating more precisely in the future the effect of pinocembrin on the phosphorylation levels of MAPK family.

It is evidenced that ROS and MAPK signal pathways are involved in the regulation of NF-κB activation in response to stress. As a redox-sensitive transcription factor, NF-κB is activated via the activation of IκB-kinase complex which then phosphorylates IκB on Ser 32 and Ser 36, resulting in its ubiquitination and subsequent proteasomal degradation as well as the release of NF-κB, which can translocate into the nucleus to activate the transcription of proinflammatory target genes, such as TNF-α, IL-1β, and IL-6 [66, 67]. The protective effects of pinocembrin against Aβ-stimulated endothelial responses were also mediated by blocking NF-κB signaling pathways. However, different concentrations of pinocembrin were required to inhibit specific inflammatory transduction in these signal pathways. Only 30 μM of pinocembrin was found to significantly decrease the levels of phosphorylation of IKKα and IKKβ, which indicates a slight reduction in the concentration of the IκB-kinase complex degradation of the NF-κB signaling regulated by this compound. Activation of NF-κB needs IκBα to be phosphorylated, which then leads to targeted degradation of IκBα. The following dissociation of IκBα causes the translocation of NF-κB from the cytoplasm to the nucleus where it binds and triggers the inflammatory gene expression. All concentrations of pinocembrin tested in this study significantly attenuated the degradation of IκBα and inhibited the nuclear translocation of p65. Although multiple signal molecules are involved in the NF-κB pathway, we suggested that pinocembrin could remarkably inhibit the activation of NF-κB signal transduction by attenuating the degradation of the inhibitory protein IκBα and blocking the translocation of NF-κB p65.

The level of proinflammatory cytokines also conduces to evaluate endothelial cell injuries. In response to Aβ stimulus, a series of intracellular signaling cascades are initiated which ultimately lead to activation of inflammation and the release of proinflammatory cytokines in endothelial cells [68]. Many studies demonstrated that some of the proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, play a key role in the development and maintenance of inflammation, and this cytokine elevation is associated with neurodegenerative diseases [69]. TNF-α, IL-1β, and IL-6 may also serve as biomarkers of the NF-κB inflammatory pathway [70]. Considering that the transcription levels of these cytokines are under the control of NF-κB, we investigated whether the reduced secretion levels of TNF-α, IL-1β, and IL-6 in pinocembrin-treated cells were due to inhibition of NF-κB signaling. In line with the above findings regarding NF-κB transduction, the levels of TNF-α, IL-1β, and IL-6 in culture medium were significantly decreased by pinocembrin at all tested concentrations. Thus, we suggest that pinocembrin has anti-inflammatory effects against fAβ1–40-induced toxicity, and its mechanisms can be routed through the NF-κB signaling pathways to inhibit the secretion of TNF-α, IL-1β, and IL-6.

Further, MAPK transductions which have been implicated to be key modulators in inflammatory signaling cascades are associated with activation with NF-κB in the inflammatory response [7173]. These MAPKs regulate NF-κB activation through IκBα/β kinase activation which induces IκB degradation [72, 73]. Thus, we deduce that the NF-κB along with MAPKs may participate in the amplifying loop of the inflammatory responses after hBMECs subjected to fAβ1–40, and that the modulations of the three-tiered cascades provide a rationale to evidence the therapeutic effects of pinocembrin against fAβ1–40-mediated toxicity in hBMECs. Previous studies evidenced that the MAPKs especially p38 and JNK have been implicated in the regulation of inflammatory mediators, including the proinflammatory cytokines, which make them potential targets for anti-inflammatory therapeutics [74, 75]. Since p38 and JNK activation in the present study was more responsive to the inhibitory effects of each concentration (from 3 μM to 30 μM) of pinocembrin than ERK that required the high concentration (30 μM), it is assumed that the anti-inflammatory effect of pinocembrin against fAβ1–40 in hBMECs may depend primarily on the inhibition of the p38 MAPK and JNK activation. As another point of view, the relevant results may provide the explanation that due to the secondary effect in the inflammatory loop pinocembrin showed a slight reduction in the phosphorylation levels of IKKα and IKKβ.

Taking the results of cytotoxicity assays and inflammatory measurements together, pinocembrin is capable of reducing the fAβ1–40 damage, increasing cell survival, and decreasing the proinflammatory cytokine levels in a consistent and effective manner, suggesting that pinocembrin might affect the regulation of the balance of cell survival and inflammatory response in cerebral endothelial cells. Previous studies have shown the therapeutic role and mechanism of pinocembrin involved in Alzheimer’s-related deficits. It has been demonstrated that it is effective in conferring neurovascular protection through maintenance of neuropil ultrastructure and the reduction of glial activation and levels of inflammatory mediators in the brain [31, 32]. Pinocembrin has been shown to promote neurovascular inflammatory pathways against various types of Aβ toxicity [31, 32]. In the present study, the direct recovery of hBMECs by pinocembrin was confirmed and the underlying mechanisms were identified. Three possible intracellular signaling pathways were found to be involved in the modulation of inflammatory responses of pinocembrin in endothelial cells (Figure 6). Firstly, because pinocembrin suppresses activation of several subfamilies of MAPK-signaling cascades induced by Aβ injury in hBMECs in accordance with the inhibition of neurovascular inflammatory pathways, it is here suggested that MAPKs pathway may be one of the mechanisms by which pinocembrin inhibits overproduction of proinflammatory cytokines. Secondly, because modulation of NF-κB activation provides a mean of reducing the generation of inflammatory factors against multiple Aβ insults conducted both in this study and in previous research, it is here suggested that pinocembrin also exerts an anti-inflammatory effect through attenuating the degradation of IκBα and blocking the nuclear translocation of NF-κB p65. Thirdly, as the NF-κB along with MAPKs may participate in the amplifying loop of the inflammatory responses in our experiments, pinocembrin shows a slight reduction in the phosphorylation levels of IKK as a compensative modulation in the NF-κB signaling.

5. Conclusion

In summary, the present study demonstrates that fAβ1–40-induced cytotoxicity in hBMECs can be rescued by pinocembrin treatment. The endothelial protective effects against fAβ1–40 exhibited by pinocembrin are achieved via anti-inflammation. The mechanisms of this reversal from Aβ may be involved in the inhibition of MAPK activation, the decrease in phosphor-IKK activation, the relief of IκBα degradation, the blockage of NF-κB p65 nuclear translocation, and the reduction of proinflammatory cytokine release. Pinocembrin does not show sufficient activity on regulating the redox imbalance. Taken together, the suppression of MAPK and NF-кB signaling pathways might play a significant role in the endothelial protection of pinocembrin. In this way, it may serve as a potential therapeutic agent for BMECs in the prevention of Alzheimer’s-related deficits.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Rui Liu and Jin-ze Li contribute equally to this work.


This work was supported by National Natural Science Foundation of China (nos. 81102830 and 81373388), Peking Union Medical College Youth Fundamental Project (2012J20), the Major Scientific and Technological Special Project for “Significant New Drugs Creation” (2013ZX09J13102-05C), Specialized Research Fund for the Doctoral Program of Higher Education (no. 20111106120023), Beijing New-star Plan of Science and Technology (xx2013065), and Beijing Organization Department Excellent Talents Project (2013D009008000007). The authors would like to thank Professor Song Wu of the Department of New Drug Development of the Institute of Materia Medica within the Chinese Academy of Medical Sciences for providing pinocembrin.


  1. R. N. Kalaria, “The role of cerebral ischemia in Alzheimer's disease,” Neurobiology of Aging, vol. 21, no. 2, pp. 321–330, 2000. View at: Publisher Site | Google Scholar
  2. B. H. Han, M. Zhou, F. Abousaleh et al., “Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-β peptide, partial restoration via γ-secretase inhibition,” Journal of Neuroscience, vol. 28, no. 50, pp. 13542–13550, 2008. View at: Publisher Site | Google Scholar
  3. M. Yamada, “Cerebral amyloid angiopathy: an overview,” Neuropathology, vol. 20, no. 1, pp. 8–22, 2000. View at: Publisher Site | Google Scholar
  4. K. A. Jellinger, “Alzheimer disease and cerebrovascular pathology: An update,” Journal of Neural Transmission, vol. 109, no. 5-6, pp. 813–836, 2002. View at: Publisher Site | Google Scholar
  5. A. A. M. Rensink, R. M. W. de Waal, B. Kremer, and M. M. Verbeek, “Pathogenesis of cerebral amyloid angiopathy,” Brain Research Reviews, vol. 43, no. 2, pp. 207–223, 2003. View at: Publisher Site | Google Scholar
  6. R. N. Kalaria, “The blood-brain barrier and cerebral microcirculation in Alzheimer disease,” Cerebrovascular and Brain Metabolism Reviews, vol. 4, no. 3, pp. 226–260, 1992. View at: Google Scholar
  7. T. Uchihara, H. Akiyama, H. Kondo, and K. Ikeda, “Activated microglial cells are colocalized with perivascular deposits of amyloid-β protein in Alzheimer's disease brain,” Stroke, vol. 28, no. 10, pp. 1948–1950, 1997. View at: Publisher Site | Google Scholar
  8. J. Miao, F. Xu, J. Davis, I. Otte-Höller, M. M. Verbeek, and W. E. van Nostrand, “Cerebral microvascular amyloid β protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid β precursor protein,” The American Journal of Pathology, vol. 167, no. 2, pp. 505–515, 2005. View at: Publisher Site | Google Scholar
  9. J. E. Preston, A. R. Hipkiss, D. T. J. Himsworth, I. A. Romero, and J. N. Abbott, “Toxic effects of β-amyloid(25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and β-alanine,” Neuroscience Letters, vol. 242, no. 2, pp. 105–108, 1998. View at: Publisher Site | Google Scholar
  10. M. Folin, S. Baiguera, M. Tommasini et al., “Effects of beta-amyloid on rat neuromicrovascular endothelial cells cultured in vitro,” International Journal of Molecular Medicine, vol. 15, no. 6, pp. 929–935, 2005. View at: Google Scholar
  11. M. A. Deli, S. Veszelka, B. Csiszár et al., “Protection of the blood-brain barrier by pentosan against amyloid-β-induced toxicity,” Journal of Alzheimer's Disease, vol. 22, no. 3, pp. 777–794, 2010. View at: Publisher Site | Google Scholar
  12. F. J. Gonzalez-Velasquez and M. A. Moss, “Soluble aggregates of the amyloid-β protein activate endothelial monolayers for adhesion and subsequent transmigration of monocyte cells,” Journal of Neurochemistry, vol. 104, no. 2, pp. 500–513, 2008. View at: Publisher Site | Google Scholar
  13. J. A. Rhodin, T. N. Thomas, L. Clark, A. Garces, and M. Bryant, “In vivo cerebrovascular actions of amyloid β-peptides and the protective effect of conjugated estrogens,” Journal of Alzheimer's Disease, vol. 5, no. 4, pp. 275–286, 2003. View at: Google Scholar
  14. R. Giri, S. Selvaraj, C. A. Miller et al., “Effect of endothelial cell polarity on β-amyloid-induced migration of monocytes across normal and AD endothelium,” American Journal of Physiology—Cell Physiology, vol. 283, no. 3, pp. C895–C904, 2002. View at: Publisher Site | Google Scholar
  15. R. D. Bell and B. V. Zlokovic, “Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease,” Acta Neuropathologica, vol. 118, no. 1, pp. 103–113, 2009. View at: Publisher Site | Google Scholar
  16. K. A. Jellinger and J. Attems, “Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease,” Journal of the Neurological Sciences, vol. 229-230, pp. 37–41, 2005. View at: Publisher Site | Google Scholar
  17. E. Farkas and P. G. M. Luiten, “Cerebral microvascular pathology in aging and Alzheimer's disease,” Progress in Neurobiology, vol. 64, no. 6, pp. 575–611, 2001. View at: Publisher Site | Google Scholar
  18. Z. Suo, J. Tan, A. Placzek, F. Crawford, C. Fang, and M. Mullan, “Alzheimer's β-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40,” Brain Research, vol. 807, no. 1-2, pp. 110–117, 1998. View at: Publisher Site | Google Scholar
  19. F. J. Gonzalez-Velasquez, J. A. Kotarek, and M. A. Moss, “Soluble aggregates of the amyloid-β protein selectively stimulate permeability in human brain microvascular endothelial monolayers,” Journal of Neurochemistry, vol. 107, no. 2, pp. 466–477, 2008. View at: Publisher Site | Google Scholar
  20. N. Strazielle, J. F. Ghersi-Egea, J. Ghiso et al., “In vitro evidence that β-amyloid peptide 1–40 diffuses across the blood-brain barrier and affects its permeability,” Journal of Neuropathology & Experimental Neurology, vol. 59, no. 1, pp. 29–38, 2000. View at: Google Scholar
  21. W. Dröge, “Free radicals in the physiological control of cell function,” Physiological Reviews, vol. 82, no. 1, pp. 47–95, 2002. View at: Google Scholar
  22. Z. Liu, C. H. Nickel, and L. G. Cantley, “HGF promotes adhesion of ATP-depleted renal tubular epithelial cells in a MAPK-dependent manner,” American Journal of Physiology. Renal Physiology, vol. 281, no. 1, pp. F62–F70, 2001. View at: Google Scholar
  23. C. A. McCloskey, M. V. Kameneva, A. Uryash, D. J. Gallo, and T. R. Billiar, “Tissue hypoxia activates JNK in the liver during hemorrhagic shock,” Shock, vol. 22, no. 4, pp. 380–386, 2004. View at: Publisher Site | Google Scholar
  24. A. Wullaert, K. Heyninck, and R. Beyaert, “Mechanisms of crosstalk between TNF-induced NF-κB and JNK activation in hepatocytes,” Biochemical Pharmacology, vol. 72, no. 9, pp. 1090–1101, 2006. View at: Publisher Site | Google Scholar
  25. M. Barkett and T. D. Gilmore, “Control of apoptosis by Rel/NF-κB transcription factors,” Oncogene, vol. 18, no. 49, pp. 6910–6924, 1999. View at: Publisher Site | Google Scholar
  26. J. Dutta, Y. Fan, N. Gupta, G. Fan, and C. Gélinas, “Current insights into the regulation of programmed cell death by NF-κB,” Oncogene, vol. 25, no. 51, pp. 6800–6816, 2006. View at: Publisher Site | Google Scholar
  27. M. Gao, S. Y. Zhu, C. B. Tan, B. Xu, W. C. Zhang, and G. H. Du, “Pinocembrin protects the neurovascular unit by reducing inflammation and extracellular proteolysis in MCAO rats,” Journal of Asian Natural Products Research, vol. 12, no. 5, pp. 407–418, 2010. View at: Publisher Site | Google Scholar
  28. L. L. Shi, B. N. Chen, M. Gao et al., “The characteristics of therapeutic effect of pinocembrin in transient global brain ischemia/reperfusion rats,” Life Sciences, vol. 88, no. 11-12, pp. 521–528, 2011. View at: Publisher Site | Google Scholar
  29. R. Liu, M. Gao, Z. Yang, and G. Du, “Pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both in vivo and in vitro,” Brain Research, vol. 1216, pp. 104–115, 2008. View at: Publisher Site | Google Scholar
  30. F. Meng, R. Liu, M. Gao et al., “Pinocembrin attenuates blood-brain barrier injury induced by global cerebral ischemia-reperfusion in rats,” Brain Research, vol. 1391, pp. 93–101, 2011. View at: Publisher Site | Google Scholar
  31. R. Liu, C. Wu, D. Zhou et al., “Pinocembrin protects against β-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis,” BMC Medicine, vol. 10, article 105, 2012. View at: Publisher Site | Google Scholar
  32. R. Liu, J. Z. Li, J. K. Song et al., “Pinocembrin improves cognition and protects the NVU in Alzheimer related deficits,” Neurobiology of Aging, vol. 35, pp. 1275–1285, 2014. View at: Publisher Site | Google Scholar
  33. N. Yang, S. Qin, M. Wang et al., “Pinocembrin, a major flavonoid in propolis, improves the biological functions of EPCs derived from rat bone marrow through the PI3K-eNOS-NO signaling pathway,” Cytotechnology, vol. 65, no. 4, pp. 541–551, 2013. View at: Publisher Site | Google Scholar
  34. S. S. Tian, F. S. Jiang, K. Zhang et al., “Flavonoids from the leaves of Carya cathayensis Sarg. inhibit vascular endothelial growth factor-induced angiogenesis,” Fitoterapia, vol. 92, pp. 34–40, 2014. View at: Google Scholar
  35. L. V. Colom, M. T. Castaneda, S. Hernandez, G. Perry, S. Jaime, and A. Touhami, “Intrahippocampal amyloid-β (1-40) injections injure medial septal neurons in rats,” Current Alzheimer Research, vol. 8, no. 8, pp. 832–840, 2011. View at: Publisher Site | Google Scholar
  36. A. Jekabsone, P. K. Mander, A. Tickler, M. Sharpe, and G. C. Brown, “Fibrillar beta-amyloid peptide Aβ1-40 activates microglial proliferation via stimulating TNF-α release and H2O2 derived from NADPH oxidase: a cell culture study,” Journal of Neuroinflammation, vol. 3, article 24, 2006. View at: Publisher Site | Google Scholar
  37. L. Zhao, L. Hou, H. Sun et al., “Apigenin isolated from the medicinal plant Elsholtzia rugulosa prevents β-amyloid 25-35-induces toxicity in rat cerebral microvascular endothelial cells,” Molecules, vol. 16, no. 5, pp. 4005–4019, 2011. View at: Publisher Site | Google Scholar
  38. L. Zhao, J. L. Wang, Y. R. Wang, and X. Z. Fa, “Apigenin attenuates copper-mediated β-amyloid neurotoxicity through antioxidation, mitochondrion protection and MAPK signal inactivation in an AD cell model,” Brain Research, vol. 1492, pp. 33–45, 2013. View at: Publisher Site | Google Scholar
  39. A. Carrano, J. J. M. Hoozemans, S. M. van Der Vies, A. J. M. Rozemuller, J. van Horssen, and H. E. de Vries, “Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy,” Antioxidants and Redox Signaling, vol. 15, no. 5, pp. 1167–1178, 2011. View at: Publisher Site | Google Scholar
  40. N. Anilkumar, R. Weber, M. Zhang, A. Brewer, and A. M. Shah, “Nox4 and Nox2 NADPH oxidases mediate distinct cellular redox signaling responses to agonist stimulation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 7, pp. 1347–1354, 2008. View at: Publisher Site | Google Scholar
  41. A. Csiszar, M. Ahmad, K. E. Smith et al., “Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype,” American Journal of Pathology, vol. 168, no. 2, pp. 629–638, 2006. View at: Publisher Site | Google Scholar
  42. P. Grammas, M. Yamada, and B. Zlokovic, “The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 4, no. 3, pp. 217–223, 2002. View at: Google Scholar
  43. I. Benilova, E. Karran, and B. de Strooper, “The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes,” Nature Neuroscience, vol. 15, no. 3, pp. 349–357, 2012. View at: Publisher Site | Google Scholar
  44. S. van Wetering, J. D. van Buul, S. Quik et al., “Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells,” Journal of Cell Science, vol. 115, no. 9, pp. 1837–1846, 2002. View at: Google Scholar
  45. G. Schreibelt, G. Kooij, A. Reijerkerk et al., “Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling,” The FASEB Journal, vol. 21, no. 13, pp. 3666–3676, 2007. View at: Publisher Site | Google Scholar
  46. M. Hsu, J. Sheu, C. Lin, M. Shen, and C. Y. Hsu, “Mitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration,” Biochimica et Biophysica Acta, vol. 1800, no. 3, pp. 290–296, 2010. View at: Publisher Site | Google Scholar
  47. T.-C. Ju, S.-D. Chen, C.-C. Liu, and D.-I. Yang, “Protective effects of S-nitrosoglutathione against amyloid β-peptide neurotoxicity,” Free Radical Biology and Medicine, vol. 38, no. 7, pp. 938–949, 2005. View at: Publisher Site | Google Scholar
  48. F. J. Gonzalez-Velasquez, J. W. Reed, J. W. Fuseler et al., “Activation of brain endothelium by soluble aggregates of the amyloid-β protein involves nuclear factor-κB,” Current Alzheimer Research, vol. 8, no. 1, pp. 81–94, 2011. View at: Publisher Site | Google Scholar
  49. G. Cainelli, C. Angeloni, R. Cervellati et al., “New polyphenolic β-lactams with antioxidant activity,” Chemistry & Biodiversity, vol. 5, no. 5, pp. 811–829, 2008. View at: Publisher Site | Google Scholar
  50. J. Zhang, R. A. Stanley, A. Adaim, L. D. Melton, and M. A. Skinner, “Free radical scavenging and cytoprotective activities of phenolic antioxidants,” Molecular Nutrition and Food Research, vol. 50, no. 11, pp. 996–1005, 2006. View at: Publisher Site | Google Scholar
  51. F. Dajas, F. Rivera, F. Blasina et al., “Cell culture protection and in vivo neuroprotective capacity of flavonoids,” Neurotoxicity Research, vol. 5, no. 6, pp. 425–432, 2003. View at: Publisher Site | Google Scholar
  52. C. Echeverry, F. Arredondo, J. A. Abin-Carriquiry et al., “Pretreatment with natural flavones and neuronal cell survival after oxidative stress: a structure-activity relationship study,” Journal of Agricultural and Food Chemistry, vol. 58, no. 4, pp. 2111–2115, 2010. View at: Publisher Site | Google Scholar
  53. A. Brunet, S. R. Datta, and M. E. Greenberg, “Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway,” Current Opinion in Neurobiology, vol. 11, no. 3, pp. 297–305, 2001. View at: Publisher Site | Google Scholar
  54. W. F. Hodnick, D. L. Duval, and R. S. Pardini, “Inhibition of mitochondrial respiration and cyanide-stimulated generation of reactive oxygen species by selected flavonoids,” Biochemical Pharmacology, vol. 47, no. 3, pp. 573–580, 1994. View at: Publisher Site | Google Scholar
  55. D. Vauzour, K. Vafeiadou, A. Rodriguez-Mateos, C. Rendeiro, and J. P. E. Spencer, “The neuroprotective potential of flavonoids: a multiplicity of effects,” Genes and Nutrition, vol. 3, no. 3-4, pp. 115–126, 2008. View at: Publisher Site | Google Scholar
  56. Y. Ikeda, A. Murakami, and H. Ohigashi, “Ursolic acid promotes the release of macrophage migration inhibitory factor via ERK2 activation in resting mouse macrophages,” Biochemical Pharmacology, vol. 70, no. 10, pp. 1497–1505, 2005. View at: Publisher Site | Google Scholar
  57. N. W. Freshney, L. Rawlinson, F. Guesdon et al., “Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27,” Cell, vol. 78, no. 6, pp. 1039–1049, 1994. View at: Publisher Site | Google Scholar
  58. N. Origlia, M. Righi, S. Capsoni et al., “Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction,” Journal of Neuroscience, vol. 28, no. 13, pp. 3521–3530, 2008. View at: Publisher Site | Google Scholar
  59. A. Sanchez, D. Tripathy, X. Yin et al., “p38 MAPK: a mediator of hypoxia-induced cerebrovascular inflammation,” Journal of Alzheimer's Disease, vol. 32, no. 3, pp. 587–597, 2012. View at: Publisher Site | Google Scholar
  60. L. M. Tai, K. A. Holloway, D. K. Male, A. J. Loughlin, and I. A. Romero, “Amyloid-β-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation,” Journal of Cellular and Molecular Medicine, vol. 14, no. 5, pp. 1101–1112, 2010. View at: Publisher Site | Google Scholar
  61. S. Eminel, A. Klettnert, L. Roemer, T. Herdegen, and V. Waetzig, “JNK2 translocates to the mitochondria and mediates cytochrome c release in PC12 cells in response to 6-hydroxydopamine,” Journal of Biological Chemistry, vol. 279, no. 53, pp. 55385–55392, 2004. View at: Publisher Site | Google Scholar
  62. C. Tournier, P. Hess, D. D. Yang et al., “Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway,” Science, vol. 288, no. 5467, pp. 870–874, 2000. View at: Publisher Site | Google Scholar
  63. M. Sato, D. Bagchi, A. Tosaki, and D. K. Das, “Grape seed proanthocyanidin reduces cardiomyocyte apoptosis by inhibiting ischemia/reperfusion-induced activation of JNK-1 and C-JUN,” Free Radical Biology and Medicine, vol. 31, no. 6, pp. 729–737, 2001. View at: Publisher Site | Google Scholar
  64. M. Yoshizumi, T. Kogame, Y. Suzaki et al., “Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells,” British Journal of Pharmacology, vol. 136, no. 7, pp. 1023–1032, 2002. View at: Publisher Site | Google Scholar
  65. D. Crenesse, J. Gugenheim, J. Hornoy et al., “Protein kinase activation by warm and cold hypoxia-reoxygenation in primary-cultured rat hepatocytes-JNK1/SAPK1 involvement in apoptosis,” Hepatology, vol. 32, no. 5, pp. 1029–1036, 2000. View at: Publisher Site | Google Scholar
  66. W. Chao, Y. Shen, X. Zhu et al., “Lipopolysaccharide improves cardiomyocyte survival and function after serum deprivation,” Journal of Biological Chemistry, vol. 280, no. 23, pp. 21997–22005, 2005. View at: Publisher Site | Google Scholar
  67. C. Dogra, H. Changotra, S. Mohan, and A. Kumar, “Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-κB and degradation of MyoD protein,” The Journal of Biological Chemistry, vol. 281, no. 15, pp. 10327–10336, 2006. View at: Publisher Site | Google Scholar
  68. A. M. Szczepanik and G. E. Ringheim, “IL-10 and glucocorticoids inhibit Aβ(1–42) and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system,” Journal of Alzheimer's Disease, vol. 5, no. 2, pp. 105–117, 2003. View at: Google Scholar
  69. N. L. Monson, S. J. Ireland, A. J. Ligocki et al., “Elevated CNS inflammation in patients with preclinical Alzheimer's disease,” Journal of Cerebral Blood Flow & Metabolism, vol. 34, no. 1, pp. 30–33, 2014. View at: Publisher Site | Google Scholar
  70. C. Li, W. Browder, and R. L. Kao, “Early activation of transcription factor NF-κB during ischemia in perfused rat heart,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 276, no. 2, pp. H543–H552, 1999. View at: Google Scholar
  71. N. Sakai, T. Wada, K. Furuichi et al., “p38 MAPK phosphorylation and NF-κB activation in human crescentic glomerulonephritis,” Nephrology Dialysis Transplantation, vol. 17, no. 6, pp. 998–1004, 2002. View at: Publisher Site | Google Scholar
  72. B.-C. Che and W.-W. Lin, “PKC- and ERK-dependent activation of IκB kinase by lipopolysaccharide in macrophages: enhancement by P2Y receptor-mediated CaMK activation,” British Journal of Pharmacology, vol. 134, no. 5, pp. 1055–1065, 2001. View at: Publisher Site | Google Scholar
  73. I. N. Hsieh, A. S. Chang, C. M. Teng, C. C. Chen, and C. R. Yang, “Aciculatin inhibits lipopolysaccharide-mediated inducible nitric oxide synthase and cyclooxygenase-2 expression via suppressing NF-B and JNK/p38 MAPK activation pathways,” Journal of Biomedical Science, vol. 18, no. 1, article 28, 2011. View at: Publisher Site | Google Scholar
  74. G. L. Johnson and R. Lapadat, “Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases,” Science, vol. 298, no. 5600, pp. 1911–1912, 2002. View at: Publisher Site | Google Scholar
  75. J. X. Wang, L. F. Hou, Y. Yang, W. Tang, Y. Li, and J. P. Zuo, “SM905, an artemisinin derivative, inhibited NO and pro-inflammatory cytokine production by suppressing MAPK and NF-kappaB pathways in RAW 264.7 macrophages,” Acta Pharmacologica Sinica, vol. 30, no. 10, pp. 1428–1435, 2009. View at: Publisher Site | Google Scholar

Copyright © 2014 Rui Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.